Navigation Links
Targeting nicotine receptors to treat cognitive impairments in schizophrenia
Date:1/11/2011

Smoking is a common problem for patients with schizophrenia. The increased tendency of patients diagnosed with this disorder is to not only smoke, but to do so more heavily than the general public. This raises the possibility that nicotine may be acting as a treatment for some symptoms of schizophrenia.

Nicotine acts through two general classes of brain receptors, those with high and low affinity for nicotine. The low affinity class of nicotinic receptors contains the alpha-7 subunit, which is present in reduced numbers in people with schizophrenia.

Two papers published in the January 1st issue of Biological Psychiatry suggest that drugs that stimulate these alpha-7 subunit-containing nicotinic receptors might enhance cortical function and treat cognitive impairments associated with schizophrenia.

In their study of healthy monkeys, Graham Williams and colleagues at Yale University and AstraZeneca found that very low doses of AZD0328, a novel drug that acts as an alpha-7 agonist, produced both acute and persistent improvements in their performance on a spatial working memory task.

"Our work demonstrates that that the neuronal nicotinic alpha-7 receptor plays a critical role in the core cognitive function of working memory, which is a key indicator of outcome in patients with schizophrenia," explained Dr. Williams. "The function of the alpha-7 receptor may account for the ability of a partial agonist to induce long-term beneficial changes for high-order cognition at such low doses."

This influence on cortical function has been exemplified by the work of Jason Tregellas and colleagues. These researchers examined the effects of DMXB-A, a novel alpha-7 partial agonist, on the brain's 'default network' in people with schizophrenia. Function of the default network, which is likely a major contributor to the intrinsic neuronal activity that accounts for 60-80% of the brain's energy use, is different in people with schizophrenia.

Dr. Tregellas summarized their findings: "We found that DMXB-A altered default network activity in people with schizophrenia in a pattern consistent with improved function of the network. We also found that these neuronal differences were related to the genotype of the alpha-7 nicotinic receptor and to drug-related improvements in symptoms."

Together, "these two studies provide additional support for a novel pharmacologic approach to treat cognitive impairments in schizophrenia", observed Dr. John Krystal, Editor of Biological Psychiatry.


'/>"/>

Contact: Chris J. Pfister
C.Pfister@elsevier.com
215-239-3266
Elsevier
Source:Eurekalert

Related medicine news :

1. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
2. Targeting leukemia cells gene addiction presents new strategy for treatment
3. Americans for Responsible Health Care Launch Radio Ads Targeting Seven Democrats, Warning The People Are Watching...
4. Targeting blood vessels, immune system may offer way to stop infection-caused inflammation
5. Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations
6. Targeting cell pathway may prevent relapse of leukemia
7. Age Management Leader Goes Beyond 2010 NANES Study Reqs, Targeting Heightened Obesity Group, Adult 40+
8. New Study on Elder Care Marketing Reveals Fresh Insights in Targeting Aging Population
9. Targeting the blood-brain barrier may delay progression of Alzheimers disease
10. Spanish gene expression data promise targeting of anti-angiogenesis treatment
11. Targeting disease remission has socio-economic benefits over low disease activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Dignity Health ... General Hospital Emergency Room –Mesa. The new facility is licensed under Dignity ... , “Dr. Bingham is an excellent leader and will ensure our new freestanding emergency ...
(Date:2/11/2016)... , ... February 11, 2016 , ... “ HEALING MIND ... through a Well Managed Mind” (published by Balboa Press) teaches readers how to become ... being through profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding of how ...
(Date:2/11/2016)... ... February 11, 2016 , ... SPH Analytics ... action analytics leader’s population health solutions, MDinsight® and IndiGO®, for its primary care ... healthcare system. Details of the contract were not disclosed. , As the healthcare ...
(Date:2/11/2016)... ... February 11, 2016 , ... Registered nurses, licensed practical nurses and nursing aides ... Time to Act, Time to Heal” on Thursday, February 25 from 9:00 to 11:00 ... is Vishal Chedda, president of ANSA Consultants, who will discuss clinical best practices throughout ...
(Date:2/11/2016)... ... February 11, 2016 , ... Florida Hospital presents Heart Health ... the St. Louis Blues at the Amalie Arena. The puck drops at 6:00pm, but ... exhibit, the MEGA Heart, prior to the game. The MEGA Heart will be located ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... WESTPORT, Conn. , Feb. 11, 2016  AfterPill.com ... decision to recommend alcohol abstinence for all women who ... women in the U.S. each year and raises the ... --> --> According to the ... U.S., 70% of women of child-bearing age, who have ...
(Date:2/11/2016)... Wearable posture tracker, ALEX , has taken Kickstarter by storm, crowdfunding over $60,000 – or 120% ... ALEX is said to be delivered to backers starting May of this year. ... ... ... Created by NAMU, a team of biomedical engineers out ...
(Date:2/11/2016)... ANKENY, Iowa , Feb. 11, 2016  Proliant ... New Zealand Bovine Serum Albumin (BSA) manufacturing facility.  The ... New Zealand , in Feilding. ... installation was done to functionally duplicate the systems in ... the same vendors used for U.S. installations.  ...
Breaking Medicine Technology: